Breaking News

  • 1 day ago

  • Simantini Singh Deo

Commit Biologics Appoints Thomas L. F. Montgomery Andresen, Ph.D., As CEO As Company Prepares To Enter Clinical Development Following €21.5M Seed Backing From Novo Holdings
Breaking News

More News

Clearmind Medicine Begins Enrollment For Third Cohort In FDA-Approved Phase I/IIa Trial Of Non-Hallucinogenic AUD Treatment CMND-100

Clearmind Medicine Begins Enrollment For Third Cohort In FDA-Approved ...

Simantini Singh Deo

Ad
Advertisement
Ad
Advertisement
Pharma Now

Weekly Pharma insights directly in your inbox

Get most important news delivered to your email inbox

Pharma Now

Weekly Pharma insights directly in your inbox

Get most important news delivered to your email inbox

Ad
Advertisement